Applying the APV Method in Startup Valuation: Capital Structure Changes Across Multiple Funding Rounds

The HKEX’s 2024–2025 review of Chapter 18C specialist technology company listings, alongside the SFC’s ongoing scrutiny of pre-IPO valuation methodologies in enforcement cases (SFC Enforcement Report 2024), has exposed a structural gap in how early-stage ventures communicate their worth to institutional investors. The adjusted present value (APV) method, long confined to academic capital structure textbooks and leveraged buyout models, has become a practical necessity for startups navigating multiple funding rounds with shifting debt-to-equity profiles. Under the traditional discounted cash flow (DCF) framework, the weighted average cost of capital (WACC) must be recalculated at each round—an exercise that introduces circularity when leverage ratios change materially between Series A and pre-IPO bridge financing. APV solves this by separating the unlevered firm value from the present value of financing side effects, allowing analysts to isolate the impact of each debt issuance, convertible note, or preference share tranche without re-levering the entire cost of equity. For CFOs preparing prospectus financial disclosures under HKEX Listing Rule 11.07 (profit forecasts and valuations), this separation provides a defensible audit trail—each financing decision is valued independently, reducing the risk of SFC challenge under the Code of Conduct for Corporate Finance Advisers (paragraph 15.2, fair and reasonable assumptions).

The Structural Logic of APV in Multi-Round Startup Contexts

APV’s core advantage for startups lies in its ability to decouple operating performance from financial engineering. In a typical Hong Kong-headquartered biotech firm progressing through three funding rounds—Series A (HKD 80 million equity), Series B (HKD 150 million convertible notes), and Series C (HKD 300 million preference shares with a 12% cumulative dividend)—the capital structure shifts from 100% equity to a hybrid mix with embedded debt-like obligations. The DCF-WACC approach would require re-estimating the cost of equity at each round, introducing subjectivity in the beta re-levering step (Hamada equation) and the assumed tax shield benefits. APV sidesteps this entirely by first valuing the firm as if it were all-equity financed, then adding the net present value of each financing instrument.

The unlevered cost of equity is derived from a peer group of comparable Main Board-listed healthcare firms (HKEX sector classification: Health Care, 2024 annual data), using a market risk premium of 6.5% (Damodaran, January 2025 update) and a risk-free rate based on the 10-year HKD Exchange Fund Notes yield of 3.82% as of 31 March 2025. This unlevered rate remains constant across all funding rounds, providing a stable valuation anchor. The financing side effects—tax shields on convertible note interest, issuance costs, and preference share redemption premiums—are then calculated discretely, with each instrument’s present value discounted at the cost of debt appropriate to its risk profile.

For the Series B convertible notes (5-year maturity, 4.5% coupon, HKD 150 million), the tax shield benefit is straightforward: the corporate profits tax rate of 16.5% (Inland Revenue Ordinance, Cap. 112, section 14) applied to the annual interest expense of HKD 6.75 million, discounted at the pre-tax cost of debt of 5.2% (implied from comparable HK-listed biotech bond yields, Bloomberg BVAL as of Q1 2025). The net present value of the tax shield across five years is approximately HKD 4.2 million. The Series C preference shares, however, introduce a more complex side effect: the 12% cumulative dividend is not tax-deductible under Hong Kong tax law (IRD section 16(1) only permits deduction for interest, not dividends), but the redemption premium at a 1.5x multiple of par creates a mandatory future cash outflow. Under HKAS 32 (Financial Instruments: Presentation), this premium is classified as a financial liability, and its present value (HKD 150 million premium discounted at the cost of unsecured debt of 6.8%) reduces the APV by HKD 98.3 million. This explicit treatment prevents the overvaluation that would occur if the premium were simply included in a blended WACC.

Practical Implementation Across Funding Rounds

Round 1: All-Equity Baseline Valuation

The initial Series A round (HKD 80 million for a 25% equity stake) implies a post-money valuation of HKD 320 million. Under APV, the unlevered firm value is calculated by projecting free cash flows to the firm (FCFF) for a 10-year horizon, assuming the biotech’s lead drug candidate receives HKFDA approval in Year 5 (HKFDA guidance on orphan drug designation, 2024). The terminal value uses a perpetuity growth rate of 3.0% (Hong Kong nominal GDP growth trend, Census and Statistics Department 2024). With unlevered FCFF starting at negative HKD 45 million in Year 1 (R&D expenditure) and turning positive at HKD 28 million in Year 6, the unlevered enterprise value is HKD 298.7 million (discount rate: 10.32% unlevered cost of equity). The Series A investors’ HKD 80 million stake is therefore valued at 26.8% of the unlevered firm—consistent with the negotiated 25% when the HKD 21.3 million in issuance costs (underwriting fees, legal, audit) are deducted as a negative side effect.

Round 2: Incorporating Debt-Like Instruments

At Series B, the convertible notes introduce two valuation layers. First, the straight-debt component: HKD 150 million principal, 4.5% coupon, five-year maturity, valued at HKD 142.6 million using a market yield of 5.2% (reflecting the startup’s credit spread of 138 bps over the risk-free rate). Second, the conversion option: a 3-year call feature allowing conversion into 15% of the fully diluted equity at a 20% discount to the Series C price. Using a Black-Scholes model with 60% equity volatility (implied from HK-listed biotech options, HKEX derivatives data Q1 2025), the option value is HKD 38.4 million. The combined instrument value of HKD 181.0 million exceeds the HKD 150 million cash received, creating a negative side effect of HKD 31.0 million—the cost of the cheap conversion terms. This is added to the unlevered firm value as a reduction. The net APV after Series B becomes HKD 298.7 million (unlevered) minus HKD 21.3 million (Series A costs) minus HKD 31.0 million (Series B conversion cost) plus HKD 4.2 million (tax shield) = HKD 250.6 million. The Series A investors’ stake, now diluted by the conversion option, sees their effective ownership drop to 21.3% from 25%.

Round 3: Preference Shares and Redemption Obligations

The Series C preference shares (HKD 300 million, 12% cumulative dividend, 1.5x redemption premium at Year 7) require a bifurcated analysis under HKAS 32. The liability component—the mandatory redemption premium of HKD 150 million—is valued at HKD 98.3 million (discounted at 6.8% over seven years). The equity component—the residual dividend rights—is valued at HKD 201.7 million. The dividend payments (HKD 36 million annually) are not tax-deductible, so no tax shield arises. However, the redemption premium creates a financing side effect of negative HKD 98.3 million. The total side effects from all three rounds are: Series A costs (-HKD 21.3 million), Series B conversion cost (-HKD 31.0 million), Series B tax shield (+HKD 4.2 million), Series C redemption premium (-HKD 98.3 million). Net side effects: -HKD 146.4 million. The final APV is HKD 298.7 million minus HKD 146.4 million = HKD 152.3 million. This is substantially below the HKD 320 million Series A post-money valuation, reflecting the dilutive and costly nature of subsequent financing instruments—a reality that DCF-WACC, with its single discount rate, would obscure.

Regulatory and Disclosure Implications for Hong Kong Listings

The SFC’s Code of Conduct for Corporate Finance Advisers (paragraph 15.2) requires that all valuation assumptions be “fair and reasonable” and that the basis of any opinion be clearly disclosed. For a startup filing a listing application under Chapter 18C (specialist technology companies), the prospectus must include a valuation report that addresses the impact of all pre-IPO financing rounds on the offer price. The APV method provides a transparent, auditable framework: each financing side effect is attributed to a specific instrument, with its valuation methodology (discounted cash flow, option pricing model, or market comparable) disclosed separately. This granularity reduces the risk of an SFC query under the Misrepresentation Ordinance (Cap. 21) regarding misleading valuation statements.

HKEX Listing Rule 11.07 further requires that any profit forecast or valuation in a prospectus be supported by a statement from the sponsor confirming the basis of preparation. Under APV, the sponsor can demonstrate that the unlevered firm value is independent of the capital structure, and that each financing side effect is calculated using market-observable inputs (yields, volatilities, credit spreads) rather than assumed WACC components. For the biotech example above, the sponsor’s working papers would show: (1) unlevered FCFF projections audited by the reporting accountant under HKSA 800; (2) convertible note option values derived from HKEX-traded options data; and (3) preference share redemption premiums cross-referenced to the company’s constitutional documents and the terms of the subscription agreement.

The Hong Kong Monetary Authority’s (HKMA) supervisory policy manual on credit risk valuation (SA-2, revised 2024) also indirectly supports the APV approach for startup lenders. While the HKMA’s guidelines apply to authorized institutions, the principle of separating operating cash flows from financing effects aligns with the Basel III framework’s treatment of hybrid capital instruments. For family offices and private credit funds providing bridge loans to pre-IPO startups, APV offers a consistent methodology for assessing the impact of their debt on the equity value of existing shareholders—a critical input for covenant negotiations and collateral valuation.

Practical Limitations and Adjustments

APV is not without limitations in the startup context. The assumption of a constant unlevered cost of equity across rounds ignores the potential change in business risk as the startup progresses from R&D to commercialization. For the biotech example, the unlevered beta might decrease from 1.8 (pre-revenue) to 1.2 (post-approval), requiring a mid-round adjustment. The solution is to segment the valuation horizon: use a higher unlevered cost of equity (11.5%) for the pre-approval period (Years 1–5) and a lower rate (9.8%) for the post-approval period (Years 6–10), with the transition point aligned to the HKFDA approval milestone. This segmented APV preserves the separation of financing effects while reflecting the evolving operating risk.

Another limitation is the treatment of employee stock options (ESOPs), which are common in Hong Kong-incorporated startups under the Companies Ordinance (Cap. 622, sections 140–142). ESOPs are a financing side effect—they represent a below-market issuance of equity—but their valuation requires an option pricing model with assumptions about vesting schedules, exercise prices, and forfeiture rates. Under APV, the ESOP cost is calculated as the difference between the grant-date fair value (using a trinomial lattice model) and the expected exercise proceeds, discounted at the cost of equity. For a typical startup with 10% of fully diluted shares reserved for ESOPs at a strike price of HKD 1.00 per share (versus a current fair value of HKD 5.00), the side effect is negative HKD 0.4 million per 100,000 options granted. This must be updated at each funding round as new grants are made and existing options vest.

Actionable Takeaways for Practitioners

1. Adopt APV for any startup with more than two distinct financing instruments—convertible notes, preference shares, or ESOPs—to avoid the circularity of WACC re-levering across rounds with materially different debt-to-equity ratios.

2. Segment the unlevered cost of equity at key business milestones (product approval, revenue inflection, profitability) to reflect changing operating risk, using HKEX sector peer betas as the benchmark.

3. Disclose each financing side effect separately in valuation reports prepared for Chapter 18C listing applications, citing the specific HKEX Listing Rule (11.07) and SFC Code of Conduct (paragraph 15.2) requirements for fair and reasonable assumptions.

4. Treat preference share redemption premiums as financial liabilities under HKAS 32 and value them at the cost of unsecured debt, not the cost of equity, to avoid understating the negative side effect on equity value.

5. Update ESOP side effects at each funding round using a trinomial lattice model calibrated to the startup’s equity volatility, with vesting schedules and forfeiture rates disclosed in the prospectus’s “Share-Based Payments” note.